Colgate supports "antiplaque" statement of identity for monograph products.
This article was originally published in The Tan Sheet
Executive Summary
ANTIGINGIVITIS AGENTS "ANTIMICROBIAL" STATEMENT OF IDENTITY is "not consistent" with the deliberations of FDA's Dental Plaque Subcommittee, Sheila McGuire-Riggs, DDS, Wellmark, Blue Cross/Blue Shield of Iowa, a subcommittee member, declared at a May 28 meeting in Gaithersburg, Md. The advisory group met to discuss labeling for FDA's OTC antigingivitis drug products monograph, as well as final formulation testing requirements for products included in the rulemaking.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning